HeLa cell line, a model to study the role of cofactor of BRCA1 in cervical cancer by Abd Elhamied, Noha Saad
American University in Cairo 
AUC Knowledge Fountain 
Theses and Dissertations 
6-1-2018 
HeLa cell line, a model to study the role of cofactor of BRCA1 in 
cervical cancer 
Noha Saad Abd Elhamied 
Follow this and additional works at: https://fount.aucegypt.edu/etds 
Recommended Citation 
APA Citation 
Abd Elhamied, N. (2018).HeLa cell line, a model to study the role of cofactor of BRCA1 in cervical cancer 
[Master’s thesis, the American University in Cairo]. AUC Knowledge Fountain. 
https://fount.aucegypt.edu/etds/1344 
MLA Citation 
Abd Elhamied, Noha Saad. HeLa cell line, a model to study the role of cofactor of BRCA1 in cervical 
cancer. 2018. American University in Cairo, Master's thesis. AUC Knowledge Fountain. 
https://fount.aucegypt.edu/etds/1344 
This Thesis is brought to you for free and open access by AUC Knowledge Fountain. It has been accepted for 
inclusion in Theses and Dissertations by an authorized administrator of AUC Knowledge Fountain. For more 
information, please contact mark.muehlhaeusler@aucegypt.edu. 
       School of Sciences and Engineering 
 
 
 
HELA CELL LINE, A MODEL TO STUDY THE ROLE 
OF COFACTOR OF BRCA1 IN CERVICAL CANCER  
 
 
 
A Thesis Submitted to the 
Biotechnology Master’s Program 
 
In partial fulfilment of the requirements for the 
Degree of Master of Science 
 
 
By 
Noha Saad Abd Elhamied 
Bachelor of Pharmaceutical Sciences 
 
 
Under the supervision of 
Dr. Asma Amleh 
Associate Professor, Department of Biology 
The American University in Cairo 
 
May 2018 
 
 
 
 
ii 
 
 
The American University in Cairo 
School of Sciences and Engineering (SSE) 
 
HELA CELL LINE, A MODEL TO STUDY THE ROLE OF  
COFACTOR OF BRCA1 IN CERVICAL CANCER 
  
A Thesis Submitted by 
Noha Saad Abd Elhamied 
To the Biotechnology Master’s Program 
May 2018 
  
In partial fulfilment of the requirements for  
The degree of Master of Science in Biotechnology 
 
Has been approved by 
  
Thesis Committee Supervisor/Chair 
_______________________________________________ 
Affiliation ______________________________________  
Thesis Committee Reader/Examiner 
______________________________________________   
Affiliation _____________________________________   
Thesis Committee Reader/Examiner 
______________________________________________   
Affiliation ______________________________________   
Thesis Committee Reader/External Examiner 
______________________________________________   
Affiliation _____________________________________   
  ________________       _____________       ______________         _______________   
   Dept. Chair/Director     Date             Dean      Date   
iii 
 
 
 
 
DEDICATION 
 
To my parents, Saad Abd Elhamied Mohamed and Faten Ahmed Mosleh; this is 
because of you.  
Thank you for never letting me give up 
 
 
 
 
       
 
 
 
 
 
 
 
 
 
 
iv 
 
ACKNOWLDEGMENTS      
   All praise be to Allah  
 
I would like to express my deepest gratitude to my supervisor Dr. Asma Amleh for her 
continuous guidance and support during my thesis work. I will always be grateful for the time 
and effort she spent on putting me on the right path of scientific research. Her valuable 
discussions and suggestions were essential for the progress of the project. I will always be 
motivated by her dedication to her work and to science. 
I sincerely thank Dr. Amleh’s research team members; past and present, who have been a great 
support throughout this journey. I am deeply grateful to Menna Elfar, Menna Ghouraba, Myret 
Ghabriel, Nancy Ahmed and Sheri Saleeb for their brain storming, help in the laboratory work, 
valuable comments and for readiness to share their scientific knowledge whenever needed. I 
would like to acknowledge Eman Elzenini for her precise documentation and valuable notes 
that helped me a lot. I would like also to thank Razan Masad for her support and for her 
guidance during my first experiments. It was such a blessing to work with this amazing team.  
I would like to acknowledge Dr. Ahmed Moustafa for his continuous support to the 
Biotechnology program students. I would also like to extend my sincere appreciation to all my 
professors at the AUC, especially Dr. Hamza El Dorry who has taught me a lot during my first 
year in the program. I deeply recognize Amged Ouf for all his efforts and time spent on 
ensuring that our research work continues smoothly.  
I am sincerely thankful to Mr. Moataz Al-Alfi for partially funding my studies at the AUC. 
Also, I would to express much gratitude to the AUC for the research grant that supported this 
work. 
Last but not least, my deepest appreciation goes to my beloved family for their support; my 
husband Ashraf Aboelfadl and my amazing sons Mohamed, Ali and Hamza for their caring, 
patience and for all the time that I have been taking from us as a family to put into my studies 
and research work. I am truly thankful to my precious brothers, Tamer and Ahmed, and my 
sister in law Jailan Rashed for the positive energy and the unlimited emotional support they 
have been giving me throughout this learning journey. 
 
v 
 
HELA CELL LINE, A MODEL TO STUDY THE ROLE OF 
COFACTOR OF BRCA1 IN CERVICAL CANCER 
ABSTRACT 
Being one of the four subunits that makes up the Negative Elongation Factor Complex (NELF), 
Cofactor of BRCA1 (COBRA1); also known as NELF-B, is able to regulate a number of genes 
involved in cellular proliferation, metabolism, cell cycle progression and DNA repair. In 
addition, COBRA1 was shown to interact with other transcription factors such as BRCA1, AP-
1 complex and several nuclear receptors. Despite the evidences that suggest COBRA1 as a 
potential player involved in the progression of a number of cancers, its role in cervical cancer 
has not been previously investigated. To date, it has been studied in breast, upper 
gastrointestinal and liver cancers. The main objective of our study was to investigate the 
potential involvement of COBRA1 in cervical cancer progression. We first did in-silico 
analysis of the expression patterns of COBRA1 in cervical cancer tissues relative to normal 
cervical tissues using the publicly available Oncomine Cancer Microarray Database. Search 
results revealed a significant upregulation of COBRA1 in two mRNA microarray datasets. 
RNA interference technique was then used to knockdown COBRA1 expression in cervical 
cancer cell line, HeLa. Once a successful siRNA mediated silencing at the RNA and protein 
levels of COBRA1 was established and confirmed through semi-quantitative Reverse 
Transcription Polymerase Chain Reaction (RT-PCR) and Western Blot, we investigated its 
consequences on proliferation, migration and survival of HeLa cells. Interestingly, COBRA1 
depletion resulted in a significant increase in the mRNA expression of Trefoil Factor 1 (TFF1) 
accompanied by a subsequent decrease in the β-catenin mRNA levels. These findings suggests 
an effect for COBRA1 on the Wnt/β-catenin signalling pathway, which could be mediated 
through TFF1. In addition, COBRA1 silencing resulted in significant decrease in the 
expression of survivin 2B and survivin DeltaEX3 isoforms while the observed decrease in 
survivin wild type form was found to be statistically insignificant. Survivin is known to play a 
major role in cancer cells proliferation and survival. Yet, the finding that the noted decrease in 
β-catenin and survivin expression was not reflected on the proliferation and migration abilities 
of HeLa is not conclusive and requires further investigations. Taken together, these findings 
could help as an initial step in identifying the role of COBRA1 in cervical cancer tumorigenesis. 
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1.  LITERATURE REVIEW 
 
1.1 Cervical Cancer 
 
1.1.1 Incidence and Epidemiology  
 
Cervical cancer is the fourth most frequent cancer among women worldwide with 527,600 
new cases being diagnosed annually. It is the fourth cause of cancer related deaths and 
responsible for around 265,700 deaths globally per year. Cervical cancer primarily affects 
developing countries, being the second most commonly diagnosed type of cancer and third 
leading cause of cancer death among females in those countries (Arbyn et al., 2011; Torre 
et al., 2015). Over 85 % of all cervical cancer cases and related death occurs in developing 
countries. The incidence rates are lowest in Australia/New Zealand, Northern America and 
Western Europe while the highest rates are in Eastern, Western and Southern Africa, South 
America, South Central Asia together with Melanesia. Notably, the most affected are socio-
economically active young women who are in the prime of their lives (Arbyn et al., 2011). 
This variation is mainly attributed to differences in the availability of efficient screening 
tools allowing for the early detection and removal of precancerous lesions. (Arbyn et al., 
2011; Torre et al., 2015).  
Based on the information available from ICO/IARC Information Centre on HPV and 
Cancer, cervical cancer is the 13th most frequent cancer among women in Egypt and ranks 
as the 10th most frequent cancer among women between the ages of 15 and 44 years. It 
accounts for a total number of 866 cancer new cases and 373 cancer related death annually 
(http://www.hpvcentre.net, last accesses April 2018) (Bruni et al.,2017). 
 
1.1.2 Aetiology 
 
Almost all cervical tumours (99%) develop as a result of persistent human papilloma virus 
(HPV) infection (Colombo et al., 2012). Human papillomaviruses are DNA viruses that 
infect and replicate in cutaneous and mucosal epithelia. Oncogenic subtypes such as HPV 
16 and 18 account for 70% of all cervical malignancies. Other oncogenic subtypes include 
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HPV 31, 33, 35, 39, 45, 51, 52, 53, 56, 58, 59, 66, 68, 73 and 82. Studies suggest that genetic 
sequences variations among different HPV subtypes could produce differences in their 
oncogenic potentials and hence different clinical outcomes among CC patients.  (Dasari, 
Wudayagiri, & Valluru, 2015).  
When HPV infection occurs, it is usually eliminated by the immune system. If viral 
elimination does not happen, prolonged presence of the oncogenic HPV subtype and 
increased viral load occur leading to higher chances of developing a precancerous cervical 
intraepithelial neoplastic (CIN) lesion, which can progress to invasive cervical tumors. Risk 
cofactors that can halt the process of HPV elimination include the presence of defective 
immune response as with human immunodeficiency virus (HIV) infection and the use of 
organ transplant rejection drugs. Smoking can also be a cofactor for the development of 
chronic HPV infection  (Newton & Mould, 2017; Uyar & Rader, 2014). It is worth 
mentioning that also estrogen contributes to HPV infection persistence and the resulting 
neoplastic progression via  increasing viral oncogenes expression (S. H. Chung, 
Franceschi, & Lambert, 2010; Nair et al., 2005). 
Cervical cancer is more common than other HPV derived cancers (vagina, vulva, penile, 
anal and oropharynx) due to the presence of a transformation zone on the cervix. This is 
mainly an area of exposed columnar tissue on the cervix known as the ectropion which 
undergoes squamous metaplasia and transforms into squamous tissue, hence the label 
transformation zone. This area is  highly susceptible to the effects of oncogenic HPV 
(Newton & Mould, 2017). 
 
1.1.3 Surveillance and Diagnosis 
 
Cervical epithelial tumors are classified by WHO into three main categories; squamous (70-
80%), adenocarcinoma (10-15%) and other epithelial tumors (including neuroendocrine 
tumors and undifferentiated carcinoma) (Colombo et al., 2012). Despite the decline in the 
incidence of CC in developed countries, several reports during the past 40 years have 
documented an increase in relative distribution of the adenocarcinoma subtype compared to 
squamous cell carcinoma in these countries (Gien, Beauchemin, & Thomas, 2010; 
Hildesheim & Berrington de González, 2006) . 
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Symptoms associated with early stages of CC are usually non-specific and are common with 
other clinical conditions. The most common sign suggesting the presence of cervical cancer 
is bleeding; which could be postcoital, intermenstrual or postmenopausal bleeding. Other 
symptoms include blood stained vaginal discharges, pelvic pain and suspicious cervix on 
examination. The lateral spread of the tumor which is present in advanced stages of CC can 
result in the occurrence of loin pain caused by hydro-nephrosis, sciatica with tumor 
compressing nerve roots and deep vein thrombosis causing swollen legs (Newton & Mould, 
2017). 
Screening techniques for CC mainly include cell cytology and HPV-DNA testing. The basic 
widely used cytology screening test for CC is the Papanicolaou (Pap) smear. It involves 
sampling the epithelial cells from the surface of cervix and assessing their morphology. 
Implementing this screening method in some parts of the world has resulted in a significant 
decrease in the incidence of CC. Still, the Pap smear test suffers from lack of sensitivity, 
being of subjective nature and it might not be as efficient for the detection of 
adenocarcinoma subtype. In 2008, molecular HPV-DNA testing has been employed as a 
new screening approach with greater diagnostic sensitivity and reproducibility especially 
when detecting precancerous stages (Colombo et al., 2012).  
Although cervical cancer can be detected in its early stages by the above mentioned 
techniques, hence can be successfully eradicated through surgery, curative treatments do not 
yet exist for advanced, recurrent or metastatic stages of the disease (Cao, Liu, Yang, Chen, 
& Zheng, 2017). 
 
1.1.4 Vaccination 
 
The notion that HPV infection is a main contributor in the development of CC has facilitated 
the measures taken for CC prevention through the development of HPV vaccines. HPV 
vaccination has been the primary prophylactic strategy for CC with a number of vaccines 
being developed and are of wide use in some countries across the world. In 2006, FDA 
approved Gardasil [Merck and Company, Whitehouse Station, NJ], a quadrivalent vaccine 
developed for the prevention of diseases associated with infection with different HPV types 
(6, 11, 16 and 18).  Two additional vaccines were approved for use in 2009 and  2014: 
Ceravix [GlaxoSmithKline, Brentford, UK], a bivalent vaccine against HPV types 16 and 
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18, and Gardasil 9 [Merck], the most advanced prophylactic vaccine to date, which protects 
against nine HPV types: 6, 11, 16, 18, 31,33, 45, 52 and 58 (Newton & Mould, 2017). Some 
concerns have been raised regarding the use of vaccines which are mainly that they were 
tailored towards the population within the developed countries with decreased potency in 
developing countries; where they are needed most. In addition, the high cost stands against 
the wide scale use of the vaccines in the developing parts of the world. 
It is highly recommended that all women; including those previously vaccinated, continue 
to be screened. This is mainly because HPV vaccines do not have any therapeutic effects so 
they cannot protect against already established infections, together with the fact that they do 
not protect against all of the other types of high risk HPVs that can cause cervical cancer. 
Unfortunately, many low-resource countries do not have the technical and public health 
infrastructure needed to support Pap smear testing; the most common screening tool for 
cervical cancer in more developed countries (Pyeon et al., 2007; Torre et al., 2015). 
 
1.1.5 Prognosis and Available Treatments 
 
Prognostic factors for survival rate in CC patients include the clinical stage, lymph node 
state, size of the tumor and grade (Gien et al., 2010). The cancer stage and tumour size are 
currently the basis for choosing suitable treatment. Surgical options for patients with early 
stage disease (FIGO stage IA- IB1, in which the lesion is confined to the cervix) include 
cervical conisation, hysterectomy and pelvic trachelectomy, with 5 years survival rates that 
exceeds 90%. In stages ⅡB2- ⅢB, it becomes more challenging to obtain negative surgical 
margins; in these instances surgery, chemotherapy and/or radiation is given in combination 
aiming to improve treatment results (Colombo et al., 2012; Newton & Mould, 2017). 
 For women with cancers that have spread within the region, the 5-years survival rates falls 
to 57% and for cancers which have metastasised to distant organs survival is estimated at 
only 17%. For the more advanced stages of the disease (stage Ⅳ), surgery could not remain 
an available option and the treatment is usually palliative with the objective of controlling 
symptoms and improving quality of life (Colombo et al., 2012; Newton & Mould, 2017).  
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1.1.6 Molecular Biology of CC Progression 
 
Identifying the molecular mechanisms involved in cervical carcinogenesis is essential for 
developing therapeutic targets and biomarkers that would allow for better management of 
the disease. The fact that not all women infected with HPV will develop CC has shed the 
light that other factors in addition to HPV infection are involved.  HPV DNA integration 
into the host chromosomal genome is a crucial step in cervical cancer progression and is 
almost present in all invasive CC. This integration usually occurs at common fragile sites in 
the human genome.  During this process, cleavage occurs at the E1/E2 genes cleavage site 
leading to deletion of E2 gene, thus leading to overexpression of E6 and E7 viral 
oncoproteins whose expression is repressed by E2. This in turn promotes genomic 
instability, accumulation of secondary mutations, and malignant transformation of the host 
cells. In addition, the virus integrates into host genes and regulatory elements with the 
possibility of inducing structural alteration of the host genome and transcriptional 
deregulation of normal genetic expression (Pérez-Plasencia, Dueñas-Gonzalez, & Bustos-
Martínez, 2008; Uyar & Rader, 2014). 
The expression of certain proteins of the host cells such as those involved in cell division 
and apoptosis are altered by the viral oncoproteins. The E7 protein can bind to tumor-
suppressor proteins of the retinoblastoma (pRB) family, and degrades them leading to 
uncontrolled activation of E2F transcription factors which in turn stimulate expression of 
genes involved in S phase of the cell cycle. In addition, E7 interacts with the cyclin-
dependent kinases (CDK) inhibitors, p21 and p27, promoting the transition from G1 to S 
phase. The E6 protein in turn halts the pro-apoptotic effect of p53, BCL2 Associated X 
protein (BAX), BCL2 Antagonist /Killer (BAK) and c-Myc. The E5 viral protein is mainly 
active during early stages of the disease before viral DNA integration occurs. One of its 
main activities is the interaction with epidermal growth factor receptor (EGFR) leading to 
increased cellular proliferation rate  (De Freitas, Coimbra, & Leitão, 2014). 
Improved understanding and increased knowledge of the molecular biology events 
associated with CC progression will help develop novel treatment strategies. The main 
interest of this study is COBRA1 gene, which have been recently identified for having a 
potential role in the progression of several cancers. 
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1.2 Cofactor of BRCA1 
 
1.2.1 Identification 
 
Cofactor of BRCA1; also known as NELF-B, was first isolated from a human ovary cDNA 
library. It is located on chromosome 9 and encodes a 580 amino acid protein with 3 repeats 
of the LXXLL motif, where L-leucine and X-any amino acid.  It has been first identified as 
a BRCA1 interacting protein via a yeast two-hybrid assay. Results suggested that BRCA1-
dependent unfolding of higher levels of chromatin structure is likely to be partially mediated 
through recruitment of COBRA1to the BRCT1 domain of BRCA1  (Ye et al., 2001). Later 
in 2003, COBRA1 was found to be the same as NELF-B, which is one of the four subunits 
that constitute the negative elongation factor (NELF) complex (Narita et al., 2003). It has 
been proved that COBRA1 is involved in the transcriptional regulatory machinery of the 
cells and is involved in the regulation of multiple considerably important genes (Aiyar et 
al., 2004; Aiyar, Blair, Hopkinson, Bekiranov, & Li, 2007; Aiyar, Cho, Lee, & Li, 2007).  
In addition, in-vivo studies by Amleh et al., (2009) shed the light on an important role for 
COBRA1 in early embryogenesis where the general knockout of COBRA1 in murine 
embryos was found to be lethal. COBRA1 was also  found to be involved in maintaining the 
undifferentiated state of mouse ESCs (Amleh et al., 2009).  
 
1.2.2 COBRA1 and Transcription factors 
 
With no DNA binding domain of its own, COBRA1 was found to regulate the transcription 
of its downstream target genes via interacting with other transcription factors including 
BRCA1, nuclear receptors and AP-1 complex (Aiyar et al., 2004; Sun, Blair, Aiyar, & Li, 
2007; Ye et al., 2001; Zhong et al., 2004). This network of interactions suggests COBRA1 
being involved in the regulation of multiple cellular processes as proliferation, cell survival 
and tumorigenesis.  An overview of the available knowledge on COBRA1 interactions with 
various transcription factors will be discussed next. 
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1.2.2.1 BRCA1 
 
The Breast Cancer Type 1 susceptibility protein (BRCA1) gene; encoding a 1,863 amino 
acid protein, was identified and cloned in 1994 (Rosen, Fan, Pestell, & Goldberg, 2003). 
It has been linked to breast and ovarian cancers, with mutations in BRCA1 accounting for 
only 2-3% of all breast cancers; yet its expression is frequently reduced or absent in sporadic 
cancers. The tumor suppressor activity of BRCA1 has been extensively investigated and 
have been attributed to its involvement in several molecular functions including DNA repair, 
DNA damage response, cell cycle check points, regulation of certain transcriptional 
pathways and apoptosis (Rosen et al., 2003). 
In accordance with BRCA1’s reported role as tumor suppressor in breast cancer, several 
studies had shed the light on the role of COBRA1 as being a breast cancer tumor suppressor 
as well. Aiyar et al., 2007 used gene expression profiling in T47D breast cancer cell line to 
uncover a significant overlap of the genes that are regulated by COBRA1 and BRCA1, of 
which multiple genes are known to be involved in breast cancer progression (Aiyar, Cho, 
et al., 2007).  
 
1.2.2.2 NELF Complex 
 
COBRA1 was identified as being the same as NELF-B, one of the four subunits that makes 
up the negative elongation factor (NELF) complex (Narita et al., 2003). This complex is 
made up of NELF-A (66 kDa), NELF-B (62 kDa), NELF-C (60 kDa) or NELF- D (59 kDa) 
and NELF-E (46 kDa). Being translational variants of a common mRNA, either NELF-C or 
NELF-D will be present at a certain point within the NELF complex. The core of the 
complex consists of NELF-C/D together with NELF-B bridging NELF-A; having the 
RNAPⅡ binding domain and NELF-E; having the RNA binding domain (Narita et al., 
2003; Sims, Belotserkovskaya, & Reinberg, 2004).  
NELF complex together with DRB- sensitivity inducing factor (DSIF) have been associated 
with a process known as promoter proximal pausing, in which the RNA polymerase Ⅱ 
(RNAPⅡ) is stalled 30-50 bps downstream of the transcription initiation site (Yamaguchi 
et al., 1999). The kinase activity of the positive transcription elongation factor b (P-TEFb) 
causes the release of paused polymerase into productive elongation phase again by 
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phosphorylating the serine 2 position of the C-terminal domain in the largest subunit of 
RNAPII (Sun & Li, 2010). 
It is worth mentioning that all the four subunits; NELF-A, NELF-B, NELF-C/D and NELF-
E, are required for the assembly of a functional NELF complex (Narita et al., 2003). This 
was found consistent in several studies, where the knockdown of any of the four subunits 
resulted in co-depletion of the other ones at the protein level but not at the mRNA level 
(Narita et al., 2003; Sun et al., 2008; Sun & Li, 2010). 
The NELF complex mediated stalling of RNAPⅡ has been recently found to have functional 
consequences other than transcription inhibition. Studies done in Drosophila revealed that 
stalled RNAPⅡ  was associated with the promoters of around 50% of most of its highly 
expressed genes indicating a role in fine tuning of gene expression rather than inhibiting it, 
thus potentiating genes for future activation (Gilchrist et al., 2008, 2010). In addition, recent 
studies in human cells have been proposing a positive role for NELF Complex in the 
transcription activation of a large number of genes particularly those involved in cell cycle 
regulation (Sun & Li, 2010). Based on results obtained from gene expression profiling 
analysis following depletion of NELF subunits in T47D breast cancer cell line, it was 
suggested that NELF complex mainly functions in sustaining active expression of target 
genes rather than inhibiting it  through promoting association of RNAPⅡ with the actively 
transcribing genes rather than preventing the active transcription elongation. This was 
thought to be mediated through maintaining a permissive chromatin structure and preventing 
nucleosomal encroachment at promoters of target genes  (Sun et al., 2011; Sun & Li, 2010). 
  
1.2.2.3 AP-1 Complex 
 
COBRA1 has no DNA binding domains, hence its ability to regulate genetic expression is 
mainly through interaction with other transcription factors. In addition to its roles with 
BRCA1 and as a functional component of  NELF complex, it was shown to act as a 
regulatory transcription cofactor for Activator Protein-1 complex (AP-1), whose signalling 
pathways plays a major role in determining the cellular fate (Zhong et al., 2004). 
The activating protein1 (AP-1) is a transcription factor which regulates basal and inducible 
transcription of multiple genes having the consensus AP-1 sites. Within the complex cellular 
context, AP-1 activity is regulated in response to several stimuli including cytokines, stress 
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signals, growth factors, and infections in addition to oncoproteins (Hess, Angel, & 
Schorpp-Kistner, 2004) 
AP-1 have been found to be implicated in the control of both cell survival and apoptotic 
pathways (Shaulian & Karin, 2001). The modulation of this decision was found to be 
dependent on cell lineage, abundance of different AP-1 complex members, 
microenvironment, type of stimulus and the presence of regulatory transcription cofactors 
(Hess et al., 2004; Shaulian & Karin, 2001). 
COBRA1 has been proposed as one of the cofactors affecting AP-1 activity. In 2004, a study 
by Zhong et al. revealed that the overexpression of COBRA1 inhibited AP-1 mediated 
transcriptional activation in transfected cells with the opposite effect observed when 
silencing of COBRA1 with small interfering RNA was applied. This effect was attributed to 
a physical interaction between COBRA1 and AP-1 family members’ c-Jun and c-Fos 
causing an inhibition of the AP-1 transactivation of target genes. Given that the activity of 
AP-1 is effective on the cellular proliferation, differentiation, survival, apoptosis and 
malignant transformation, it was proposed that COBRA1; by acting as a cofactor in AP-1 
transactivation, is involved in the regulation of these cellular processes as well (Zhong et 
al., 2004). 
1.2.2.4 Nuclear receptors 
 
The ligand binding activation of ER induces conformational changes and activation of the 
receptor and its subsequent binding to the estrogen responsive elements in promoters of 
target genes (Aiyar et al., 2004; S. Chung, Franceschi, & Lambert, 2010). 
A novel role for COBRA1 in the regulation of hormone-responsive transcription was 
identified by Aiyar et al., (2004).  It was found that COBRA1 can bind directly to the 
activated ER-α and repress genetic transcription mediated through ER-α. These findings 
supported a role for COBRA1 in suppressing estrogen-dependent growth of breast cancer 
cells (Aiyar et al., 2004). This was attributed to the previously identified 3 repeats of the 
LXXLL motif present in COBRA1 protein needed for NR-binding (Ye et al., 2001). 
COBRA1 was found to interact with variable affinities to other nuclear receptors as the 
progesterone receptor B (PRB), androgen receptor (AR) and glucocorticoid receptor (GR). 
The strongest binding affinity was found to be related to the AR resulting in the subsequent 
regulation of the AR-dependant transcription (Sun et al., 2007). 
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1.3 Role of COBRA1 in Cancer 
 
The biological role of COBRA1 in cancer pathogenesis is not fully understood but there is 
a growing body of evidences which suggests that COBRA1 plays a role in the malignant 
transformation, proliferation and invasion of cancer cells. Previous findings are suggesting 
a cancer-type dependent role for COBRA1, with different expression patterns in different 
cancers. To date it has been studied in breast, UGCs and liver cancers. 
1.3.1 Breast Cancer 
The identification of COBRA1 as a BRCA1 interacting protein has highlighted the 
possibility of COBRA1 having a role in breast cancer. Several studies have previously 
identified COBRA1 to act as a tumor suppressor in breast cancer. In a study by Zhu et al. 
(2004), COBRA1 mRNA and protein levels were found to be differentially expressed in 
different breast cancer cell lines. Its role in the regulation of breast cancer growth was 
proposed based on the identified physical interaction between endogenous COBRA1 and 
BRCA1 within the examined cells. In addition,  both ER- positive and ER-negative cell lines 
were found to express COBRA1 suggesting absence of correlation between ER and 
COBRA1 expression (J. Zhu et al., 2004). Another study in 2004 done by Aiyar et al. on 
breast cancer cells showed that COBRA1; as being the NELF-B subunit of NELF complex, 
binds to the activated ER-α causing the RNA polymerase II to pause at  the promoter 
proximal region and thus attenuate the ERα mediated transcription activation. The use of 
siRNAs targeting COBRA1 in T47D breast cancer cells resulted in increased cellular 
proliferation. However this increase was observed only when exogenous estrogen was added 
to culture, indicating  a possible role for COBRA1 in suppressing the estrogen-mediated 
growth of breast cancer and expression of  genes such as the Trefoil Factor 1(TFF1) known 
to be associated with breast cancer progression and metastasis (Aiyar et al., 2004). This was 
confirmed in another study where COBRA1 knockdown did not affect the cellular 
proliferation of T47D cells in the absence of estrogen (Sun & Li, 2010). In accordance, 
COBRA1 expression was found to be reduced in patients with metastatic breast cancer and 
local recurrence (Sun et al., 2008). 
1.3.2 Upper Gastrointestinal Cancers 
COBRA1 has been identified as a novel oncogene in UGCs with high expression levels of 
COBRA1 mRNA and protein observed in tumor samples compared to normal (McChesney 
et al., 2006). The overexpression of COBRA1 was found to be accompanied by 
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downregulation of TFF1 expression, which has several protective and healing roles in upper 
gastrointestinal tract and has been reported to be a tumor suppressor in UGCs (Tanaka et 
al., 2013).  This was found contradictory to its previously reported role as tumor suppresser 
in breast cancer (Aiyar et al., 2004). In addition, examining the regulatory effects of 
COBRA1 on TFF1 gene expression in gastric adenocarcinoma cell lines revealed its role as 
inhibitor of TFF1 expression was estrogen independent and NELF-E independent. It was 
found to occur by COBRA1 inhibiting the AP-1 complex activation of the TFF1 gene in 
UGC, while in breast cancer, COBRA1 inhibits hormone-dependent activation of TFF1 
through recruitment to the activated ER-α. The results highlighted the ability of COBRA1 
to regulate definite  transcription processes in different cells and tissue types via interaction 
with different transcription factors (McChesney et al., 2006). 
1.3.3 Liver Cancer 
Studies done in Dr. Amleh’s lab have revealed a potential involvement of COBRA1 in HCC 
pathogenesis. Initially, Kamel (2012) has observed frequent overexpression of COBRA1 in 
HCC tumor tissues relative to their corresponding non-tumor specimens. Yet this study was 
limited with the small sample number which made it difficult to statistically correlate 
COBRA1 expression to clinicopathological parameters (Kamel, 2012).  To further explore 
the role of COBRA1 as a potential prognostic marker for HCC, Youssef et al. (2016) 
investigated the protein and mRNA expression of COBRA1 across four different cell lines 
representing different grades of HCC. Results revealed a gradual decrease in expression of 
COBRA1 with increased HCC aggressiveness. The highest expression was observed in the 
low grade HepG2 cell line and the lowest expression in the high grade SNU-387 (Youssef, 
Shawer, Afify, & Amleh, 2016). In 2017, Silencing of COBRA1 expression in HepG2 cell 
line using RNA interference resulted in a significant decrease in the cellular proliferation 
and migration rates of HepG2. This was associated with a significant decrease in the mRNA 
expression levels of the proliferation marker Ki-67 and the proto-oncogene survivin (El 
Zeneini, Kamel, El-Meteini, & Amleh, 2017).  
1.3.4 Other Cancers 
 
In a study done on ovarian cancer, COBRA1 was found to be a downstream target of the 
RAS/MAPK signaling pathway. The inactivation of this signaling pathway in ovarian cancer 
cell lines revealed a profound downregulation of COBRA1 expression, which was 
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accompanied by decreased cellular proliferation (Pohl, 2005). This finding was consistent 
with another study done on Lung cancer (Sudhir et al., 2011).  
All previous findings provide conflicting data regarding COBRA1 and suggest it having a 
cancer-type dependent role, which in turn highlights the complexity of this molecule. As to 
our knowledge, the role of COBRA1 in cervical cancer progression has not been studied 
before. 
 
HYPOTHESIS AND SPECIFIC OBJECTIVES 
Previous studies on the role of COBRA1 in cancer progression have revealed a cancer-type 
dependant role. It has been previously implicated in restraining breast cancer while 
promoting UGCs development. Studies from our group indicated a potential role for 
COBRA1 in HCC (El Zeneini et al., 2017; Youssef et al., 2016). Very little is known about 
the role of COBRA1 in CC, hence we decided to extend the scope of our group’s research 
from HCC to CC. We hypothesize that COBRA1 could be one of the players involved in the 
pathogenesis of CC. To address this hypothesis, our study had the following four main 
objectives: 
1. In-silico analysis of the expression pattern of COBRA1 in cervical carcinoma versus 
normal cervical tissues using online publicly available microarray database. 
  
2. To achieve an efficient COBRA1 knockdown in the cervical cancer cell line, HeLa. 
The HeLa cell line is an adenocarcinoma cell line derived from Ms. Henrietta Lacks, 
a 31-years old African-American female. The cells have a characteristic cobblestone-
like, epithelial appearance and has been reported to contain human papilloma virus 
18 (HPV-18) sequences (Lucey, Nelson-Rees, & Hutchins, 2009).  
 
3. To investigate the effect of COBRA1 Knockdown on cellular proliferation and 
migration of HeLa. 
 
4. To examine the expression pattern of NELF complex subunits and some cancer 
related genes following COBRA1 silencing. 
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2. MATERIALS AND METHODS 
 
2.1 Cell lines and culture  
 
Human cervical adenocarcinoma cell line HeLa was grown in Dulbecco’s modified Eagle’s 
medium (DMEM) (GIBCO, USA) supplied with 10% fetal bovine serum (GIBCO, USA), 
100 U/ml penicillin and 100 mg/ml streptomycin (GIBCO, USA). Cells were maintained in 
a humidified incubator supplied with 5% CO2 at 37 ̊Ϲ. In all below-described experiments, 
cells in the logarithmic phase of growth from passage numbers 6-20 were used and 
propagated at 70-80% confluency according to the American type culture collection 
protocol. An inverted microscope (Olympus IX70, USA) was used to observe the cells. 
HeLa cells doubling time has been found to be approximately 25 hrs. 
 
 
2.2 Viable Cell Count 
 
Trypan Blue exclusion method was used to obtain the viable cell count prior to each 
experiment. Cells were harvested and re-suspended in fresh media by pipetting up and down 
until a homogenous cell suspension with no cell clumps was obtained. Fifty microliters (µl) 
from this cell suspension was mixed with 50 µl of 0.4% trypan blue in PBS. In each chamber 
of a haemocytometer (Hausser Scientific, USA) 10 µl of the trypan blue-cell suspension was 
loaded. The cells in each of the outer four squares in the two chambers were counted and 
the following equation was used to calculate the number of cells per 1 ml of cells suspension: 
 
Number of cells/ml = (Total numbers of viable cells in all counted squares / total number 
of counted squares) x dilution factor x10000 
 
 
2.3 RNA Interference 
 
Silencing of COBRA1 (NCBI: NM_015456) was achieved by using siGENOME 
SMARTpool (Dharmacon, M-015839-00). It is a pool of four different siRNAs targeting 
different regions of COBRA1 mRNA. Table1 includes the siRNAs target sequences and 
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corresponding exon locations of COBRA1. Other siRNAs used in this study include 
GAPDH siRNA (SI02653266) and ALLStars Negative control siRNA (SI03650318), both 
purchased from Qiagen. GAPDH siRNA was used as a positive control for the transfection 
procedures and its efficiency in delivering the siRNAs into HeLa cells. ALLStars Negative 
control siRNA has no homology to any known mammalian gene and it was used to control 
for any nonspecific effects on gene expression and phenotype that can happen as a result of 
the transfection procedure itself. All siRNAs were received as lyophilized powders and were 
re-suspended in RNase-free water as per the manufacturers’ instructions to obtain working 
solutions of final concentrations of 20 µM. 
 
Table 1. COBRA siRNAs target sequences with their corresponding exons locations 
 
siGENOME 
SMARTPool 
M-015839-00 
siRNA Target sequence Target Exon 
1 CCGAAAGCUUCACUAAGUU 9&10 
2 GCGACUUGGCCUUUGGCGA 11 
3 GAGCCUGGGACAUGAUCGA 8 
4 CGUCUAAGCUGGAGGCGUU 12 
 
 
2.4 siRNA Transfection 
 
An RNase-free environment was strictly maintained throughout all experimental 
procedures. The transfection of siRNAs (COBRA1 siRNA, ALLStars Negative control 
siRNA and GAPDH siRNA) into HeLa cells was performed in 6-well plates using 
Lipofectamine 3000 (Life Technologies). The efficiency of Lipofectamine 3000 in HeLa 
cells was assessed via forward transfection of 25nM of GAPDH siRNA for 72 hrs. 
Transfection procedures were optimized regarding the transfection protocol (forward versus 
reverse), siRNAs final concentration/well and duration of transfection. The following 
optimized conditions were maintained in all experiments. Approximately 1.5 x 105 cells 
were reverse transfected with 35 nM of siRNA using 3.75 µl of Lipofectamine 3000 
according to the manufacturer’s protocol in a final volume of 2 ml/ well. In one well of a 6-
well plate, 3.5 µl of COBRA1 siRNA solution (20 µM) was mixed with 500 µl of low serum 
opti-MEM media (Gibco). After 5 minutes, 3.75 µl of Lipofectamine was added to the well 
and left for 15-20 minutes at room temperature to allow for the formation of siRNA- Lipid 
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complex. Following this short incubation, 1.5 ml of HeLa cells suspension (approximately 
1.5 x 105 cells) in antibiotic free complete DMEM media were added to the well. The same 
procedures were repeated for the negative control siRNA. As additional controls, cells were 
either left un-transfected (Untreated) or treated with Lipofectamine only (Mock). Cells were 
maintained in culture for 72 hrs post transfection followed by harvesting for RNA and 
protein analysis. 
 
2.5 RNA Extraction 
 
Trizol reagent (Invitrogen, USA) was used to extract total RNA from HeLa cells according 
to the manufacturer's instructions. An RNase-free environment was maintained during all 
extraction procedures. The extracted RNA was dissolved in nuclease-free water (Thermo 
Scientific, USA). The concentration and purity of the RNA were measured at both 260 and 
280 nm using a SPECTROstar Nano Absorbance plate reader (BMG Labtech). RNA 
concentration was automatically computed by the devise using the following equation:  
                  [RNA concentration (µg/ml) = OD at A260 x Dilution Factor x 40]. 
 
2.6 Reverse Transcription Polymerase Chain Reaction (RT-PCR) 
 
Semi quantitative RT-PCR was used to determine the differential gene expression at the 
messenger RNA level (mRNA) among tested conditions. Total RNA (0.5 μg) was reverse 
transcribed in a final volume of 20 µl using Revert Aid First strand cDNA synthesis Kit 
(Thermo Scientific, USA) according to the manufacturer’s protocol. 
All primers used for the amplification of the selected genes are listed in Table 2. PCR 
amplifications conditions were programmed for 5 minutes at 94°C, followed by cycles of 
(denaturation at 94ºC for 30 seconds, annealing at the specified temperature for each of the 
used primers sets for 30 seconds, extension at 72ºC for 45 seconds) and ending the process 
with 10 minutes at 72ºC. The PCR products were then separated on a 1.5 - 2 % agarose gel 
depending on product size and visualized using Gel Doc EZ System (Bio-Rad, USA) 
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Table 2. RT-PCR primer sequences, PCR amplification conditions and amplicon sizes (F: 
forward primer, R: reverse primer, bp: base pair) 
Gene Primer Sequence PCR 
Condition
s 
Amplicon 
Size 
GAPDH F : 5’-CCACCCATGGCAAATTCCATGGCA-3’ 
R: 5’-TCTAGACGGCAG GTCAGGTCCACC-3’ 
60.5ºC 
27 Cycles 
598 bp 
β-ACTIN F: 5’-GCAAAGACCTGTACGCCAAC-3’ 
R: 5’-GAGACCAAAAGCCTTCATACATCTC-3’ 
58ºC 
27 Cycles  
777bp 
COBRA1 F: 5’-ACATCACCAAGCAGAGGAA-3’ 
R: 5’-GATCCAGCTGTTCCAGCTTC-3’ 
59.5ºC 
32 Cycles 
366 bp 
NELF-A F: 5’-GTCGGCAGTGAAGCTCAAGT-3’ 
R: 5’-TTCACACTCACCCACCTTTTCT-3’ 
60ºC 
35 Cycles 
250 bp 
NELF-C/D F: 5’-GAAGAAGGAGAGACCCCAGC-3’ 
R: 5’-GTGCCCAAGGCTAGTGTGAT-3’ 
56 ºC 
28 Cycles 
443 bp 
NELF-E F: 5’-TGGTGAAGTCAGGAGCCATCAG-3’ 
R: 5’-CGCCGTTCAGGGAATGAATC-3’ 
63 ºC 
28 Cycles 
565 bp 
Ki67 F: 5’-CTTTGGGTGCGACTTGACG-3’  
R: 5’-GTCGACCCCGCTCCTTTT-3’ 
60 ºC 
28 Cycles 
199 bp 
β-catenin F: 5’-ACTGGCAGCAACAGTCTTACC-3’ 
R: 5’-TTTGAAGGCAGTCTGTCGTAAT-3’ 
61 ºC 
30 Cycles 
837 bp 
survivin F: 5’-TTGAATCGCGGGACCCGTTGG -3’  
R: 5’-CAGAGGCCTCAATCCATGGCA-3’  
61 ºC 
28 Cycles 
Isoform 1: 
477 bp  
Isoform 2: 
359bp  
Isoform 3: 
546bp  
TFF1 F: 5’-TTTGGAGCAGAGAGGAGGCAATGG-3’ 
R: 5’-TGGTATTAGGATAGAAGCACCAGGG-3’ 
64 ºC 
32 Cycles 
240 bp 
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2.7 Western Blot Analysis 
 
Cells were harvested at the specified time point and washed with ice cold PBS before they 
were lysed in 1X ice-cold Laemmli Lysis Buffer (50mM Tris Ph6.8, 2% sodium dodecyl 
sulphate (SDS) and 10% glycerol). For each 1 ml of Lysis buffer, 10 µl of 100X Halt 
Protease Inhibitor Cocktail (ThermoScientific, USA) was added. Cells in Lysis buffer were 
incubated at 4°Ϲ for 40 minutes with vortexing at 10 minutes intervals followed by 
centrifugation at 14000 rpm and 4°Ϲ for 15 minutes. Supernatants were collected and were 
used to determine protein content using BCA Protein Assay Kit (Pierce Biotechnology, 
USA) according to the manufacturer’s protocol.  
Equivalent amounts (20-40 μg) of proteins diluted in lysis buffer were mixed with 4X 
loading dye (60% Glycerol, 360 mM Tris-HCl pH 6.8, 12% SDS, 0.06% bromophenol blue, 
30% beta-mercaptoethanol) in a final volume of 28 µl. Samples were boiled at 100°Ϲ  for 5 
minutes prior to being loaded onto a 12 % SDS-polyacrylamide gel and separated by 
electrophoresis at 120V. Consequently, they were blotted to a nitrocellulose membrane (GE 
Healthcare). Blotted membrane was blocked with 5% non-fat dry milk in 1X TBST (0.01% 
Tween-20 in TBS) at room temperature for 2 hrs, after which the membrane was incubated 
with primary antibodies at 4 ºC overnight. Following three times washing (5 minutes each) 
with the wash solution (1 X TBS with 0.01% Tween), the membrane was incubated with 
alkaline phosphatase conjugated secondary antibody (either goat anti-rabbit IgG (KPL) or 
goat anti-mouse (KPL) diluted as 1:20,000 in 5% non-fat milk) at RT for 2 hrs.  Three times 
of washing to remove excess secondary antibody with the wash solution was performed. For 
detection, the membrane was incubated with chromogenic substrate BCIP/NBT (KPL) until 
signals became visible with naked eye. Anti-GAPDH (Abcam, ab8245) (1:10,000 in 5% 
non-fat dry milk), Anti-β-tubulin (Sigma, T7816) (1:20,000 in 5% non-fat dry milk) and 
anti-COBRA1 (Abcam, ab167401) (1:1000 in 3% non-fat dry milk) were used as primary 
antibodies in this study. 
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2.8 MTT Assay 
 
The effect of COBRA1 silencing on the viability and proliferation of HeLa cells was 
analysed by the MTT (3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide) assay 
as previously described (Chai & Yang, 2014; Yang et al., 2009; K. Zhu, Chen, Han, 
Wang, & Wang, 2012). Briefly; for reverse transfection in 96 well plates, 0.175 µl of the 
20 μM siRNA solutions and 0.15 µl Lipofectamine 3000 were diluted with 20 µl opti-MEM 
media and mixed with 6000 cells suspended in 80 µl antibiotic free complete DMEM media 
to reach a final concentration of 35 nM of siRNAs/well. Cells were maintained in culture 
for 72h, after which media was replaced with 100 µl of fresh opti-MEM and 10 µl of 5 
mg/ml MTT solution (Serva) was added to each well. The cells were incubated for 3 hr, 
media with MTT removed and the resulting intracellular purple formazan was solubilized 
using 100 μl of dimethylsulphoxide (DMSO, Sigma). Cells were incubated with DMSO for 
5-10 min, then shacked for 2 min in dark. Absorbance was measured at 490 nm using 
SPECTROstar Nano microplate reader (BMG Labtech). The assay was run in triplicates for 
each condition (Untreated cells, Mock-treated, Negative siRNA and COBRA1 siRNA 
treated cells). Three control wells of used medium alone were used to provide the blanks for 
absorbance readings. The average of the obtained triplicate absorbance readings for each 
tested condition was used to calculate percentage cell viability as follows; 
           Percentage Cell Viability = (Absorbance of Test/ Absorbance of Control) x 100 
 
2.9 Wound Healing Assay 
 
The scratch wound healing assay was used to investigate differences in cell migration 
abilities that might occur as a result of COBRA1 silencing in HeLa cells. The assay was 
performed as previously described (El Zeneini et al., 2017; Youssef et al., 2016). In brief, 
reverse transfection of COBRA1 siRNA into HeLa cells was carried out in 12 well plate. 
Approximately 7.5 x 104   cells were reverse transfected with 35nM 0f siRNA using 1.5 μl 
of Lipofectamine 3000 according to the manufacturer’s protocol in a final volume of 1 ml. 
At 72 hours post-transfection, the cell monolayer was carefully scraped using a sterile 20 μl 
pipette tip, once vertically and once horizontally creating a cross in the center of each well 
(0 hr). Floating cells were removed by washing with media. Cells were monitored for 
additional 24 hours (24 hrs). Images were taken using phase contrast at 10X magnification 
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power at 0 hr and 24 hrs. The wound area was analysed using ImageJ software and 
percentage wound closure was calculated as follows: 
Percentage wound closure = [(Wound area0h-Wound area24h)/Wound area0h] x 100 
 
2.10 Data Mining 
 
The Oncomine cancer microarray database and integrated data-mining platform 
(http://www.oncomine.org/, last accessed April 2018) (Rhodes et al., 2004) was used to 
investigate the expression profile of COBRA1 mRNA in cervical carcinoma versus 
respective normal samples. The used filter criteria included COBRA1 gene in cancer versus 
normal analysis, cancer type was restricted to cervical cancer and data type was limited to 
mRNA microarrays. Statistical significance was automatically computed by the default 
Oncomine algorithms using a two-tailed Student’s t-test. Table 3 includes cervical cancer 
microarray datasets utilized in this study.  
The Human protein Atlas (https://www.proteinatlas.org/, last accessed April 2018) was used 
to query the expression pattern of COBRA1 in HeLa relative to other cervical carcinoma 
cell lines, in addition to HepG2 cells previously used by our group for COBRA1 silencing.  
 
2.11 Statistical Analysis of Data 
 
Image J software (National Institute of Health, USA, http://www.imagej.nih.gov/ij) was 
used for quantifying the bands intensities for PCR and Western Blot analyses. Bands were 
quantified and normalized per the used internal control. Relative differences in gene 
expression are described as fold change relative to negative siRNA transfected cells unless 
specified otherwise. Statistical analyses and graphical representations were performed using 
GraphPad Prism 5.0 (GraphPad, San Diego California USA, http://www.graphpad.com/). 
All the data represent the average ± standard deviation (SD) from three independent 
experiments unless specified otherwise. One-way ANOVA, followed by a Bonferroni post-
hoc test, was used to determine the statistical significance among multiple different 
experimental groups in case of single variable. For comparisons made between two different 
groups, statistical significance was assessed using an unpaired student's t-test (two-tailed).  
P–value less than 0.05 was considered to be statistically significant (* p <0.05, ** p <0.01,   
*** p <0.001). 
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Table 3. Oncomine Microarray datasets utilized to query the expression profiles of 
COBRA1 in cervical carcinoma compared to normal cervix samples. 
 
Study 
 
Total No. of 
Samples/Microarray 
 
Type of sample 
 
Number of 
samples/Type 
 
Reference 
 
Scotto 
Cervix 2 
 
66 
 
• Normal Cervix 
• Cervical 
Squamous Cell 
Carcinoma 
 
24 
32 
 
Scotto et 
al., 2008 
 
Pyeon 
Multi-
cancer 
 
84 
 
• Normal Cervix 
• Cervical Cancer 
 
8 
20 
 
Pyeon et 
al., 2007 
 
Zhai 
Cervix 
 
41 
 
• Normal Cervix 
• Cervical 
Squamous Cell 
Carcinoma 
• High Grade 
Cervical 
Squamous 
Intraepithelial 
Neoplasia 
 
10 
 
21 
 
7 
 
 
Zhai et al., 
2007 
 
Biewenga 
Cervix 
 
45 
 
• Normal Cervix 
• Cervical 
Squamous Cell 
Carcinoma 
 
5 
40 
 
Biewenga 
et al., 
2007 
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3. RESULTS 
 
3.1 Expression of COBRA1 mRNA in cervical cancer tissues relative to 
normal cervical tissues 
 
Publicly available microarray datasets in the Oncomine Cancer Microarray database were 
queried to investigate the expression pattern of COBRA1 in cervical cancer versus normal 
counterparts at the RNA level. The search yielded results from four different datasets, from 
four independent studies (Biewenga et al., 2008; Pyeon et al., 2007; Scotto et al., 2008; 
Zhai et al., 2007). As shown in Figure 1, COBRA1 was found to be significantly 
overexpressed in cervical cancer relative to normal cervix tissues in each of the Scotto 
Cervix and Pyeon multi-cancer studies with a fold change between  1.2 - 1.8 (p<0.05). In 
Zhai Cervix dataset, COBRA1 was found to be slightly higher than normal with a fold 
change of 1.022 but with a statistically non-significant p-value (p>0.05). On the contrary, in 
Biewenga cervix, COBRA1 was shown to be downregulated relative to normal tissues, but 
again this was found to be statistically non- significant (p>0.05).  
Results obtained from Human Protein Atlas (HPA) revealed comparable expression pattern 
of COBRA1 in each of HeLa (cervical adenocarcinoma), SiHa (cervical squamous 
carcinoma) and HepG2 (Liver cancer) cell lines. HPA results are represented as the 
transcript abundance for each protein-coding gene. It is worth mentioning that HepG2 was 
previously used by our group for successful silencing of COBRA1. Since successful siRNA 
mediated knockdown depends; among other factors, on target gene abundance (Hong, 
Jiang, Kim, Li, & Lee, 2014), HPA results suggested that HeLa could serve as a suitable 
model for COBRA1 silencing (Figure 2).  
  
3.2 Knockdown of COBRA1 in CC cell line, HeLa 
 
Based on the finding of an upregulated expression pattern for COBRA1 in CC observed 
from our in silico studies, we hypothesized that COBRA1 could have a role in CC 
tumorigenesis. Hence, we analysed the effect of COBRA1 gene silencing via siRNA-
mediated RNA interference (RNAi) in HeLa cells.  For achieving an efficient siRNA  
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Figure 1. Overexpression of COBRA1 in cervical carcinoma tissues versus normal samples. 
Publicly available microarray data in OncomineTM cancer database was searched to examine the 
expression of COBRA1 in cervical carcinoma versus normal cervix samples. Four datasets from 4 
independent studies were analysed. A] Studies showing significant overexpression of COBRA1 in 
cervical carcinoma B] Study showing slightly higher COBRA1 expression but statistically non-
significant. C] Study showing downregulation in COBRA1 expression. OncomineTM   results are 
illustrated as boxplots, with the top and bottom of the box representing the upper and lower quartiles, 
respectively and the bar across the box, the median. The bars represent the 10th and 90th percentile 
and dots represent the minimum and maximum values within each category. Number of patients in 
each category (n), fold change and P-value are indicated for each study ** P<0.01, *** P<0.001. In 
Scotto Cervix, normal samples included 21 normal cervix tissue specimens and 3 commercial RNA 
from cervix uteri. 
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Figure 2. The abundance of COBRA1 in cancerous cell lines. Human protein Atlas was queried 
to investigate the abundance of COBRA1 mRNA in HeLa cells compared to SiHa and HepG2 cancer 
cell lines. The RNA-sequencing results generated in the HPA are reported as the number of 
Transcripts per Million (TPM) of the total protein-coding transcripts.  
 
 
mediated transient knockdown, optimization of the transfection protocol regarding 
efficiency of Lipofectamine 3000 in HeLa cells, siRNA concentration, transfection method 
and transfection duration had to be first performed according to the manufacturers’ 
protocols. This optimization process was aimed at obtaining the highest possible knockdown 
efficiency at the COBRA1 protein and mRNA levels, with minimal effects on cell viability.  
 
3.2.1 Lipofectamine 3000 knockdown efficiency in HeLa cells 
 
To investigate the possibility of performing COBRA1 knockdown using Lipofectamine 
3000 reagent, knockdown of the house-keeping gene GAPDH with 25 nM of GAPDH 
specific siRNA using 3.75 µl Lipofectamine 3000 was first performed via forward 
transfection protocol. Cells were harvested 72 hrs post-transfection and results were 
evaluated at the mRNA level by semi-quantitative RT-PCR. As shown in Figure 3, 
Lipofectamine 3000 resulted in ≈ 80 % silencing of GAPDH mRNA relative to the negative 
control. 
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Figure 3. Knockdown of GAPDH in HeLa cells using Lipofectamine 3000. RNA expression was 
analysed by semi-quantitative RT-PCR. Band intensities were quantified by ImageJ and normalized 
to the internal control β-ACTIN. Relative expression is expressed as fold change to siNTC. 
siGAPDH: GAPDH siRNA, siNTC: Negative siRNA. 
  
 
3.2.2 SiRNA Concentration 
 
Different concentrations of siRNAs within the range recommended by the supplier; 25 nM, 
35 nM, and 45 nM, were tested using forward transfection protocol. Knockdown efficiency 
was assayed 72 hrs following transfection by semi-quantitative RT-PCR and Western Blot. 
As shown in Figure 4, transfecting the cells with a final concentration of 35 nM COBRA1 
siRNA/well resulted in achieving a knockdown of ≈90% at the mRNA level and the highest 
observed knockdown of ≈80% at the COBRA1 protein level. Hence, the 35 nM 
concentration was used for all subsequent siRNA transfections. Cell viability and 
morphology were observed by phase contrast microscopy 10X and were found to be 
comparable in all siRNAs treated, mock-treated and untreated cells with the volume of 
Lipofectamine used (3.75 µl).  
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Figure 4. Optimization of siRNA concentration via forward transfection. A) RNA expression 
was analysed by semi-quantitative RT-PCR. Band intensities were quantified by ImageJ and 
normalized to the internal control β-ACTIN. B) Protein expression analysed by Western Blot. Band 
intensities were quantified by ImageJ and normalized to the internal control β-TUBULIN. Relative 
expression is expressed as fold change to siNTC. siCOBRA1: COBRA1 siRNA, siNTC: Negative 
siRNA. 
 
3.2.3 Transfection Method 
 
Successful gene silencing in siRNA-mediated RNA interference (RNAi) experiments 
requires efficient uptake of siRNA into the cells. Two variations of transfection were tested: 
standard forward and reverse transfections. They mainly differ in the order and timing of the 
addition of the three necessary components of transfection: siRNA, lipid-based transfection 
reagent, and cells. In forward transfection, siRNA and Lipofectamine reagent are complexed 
in low serum media and added to pre-seeded cells that are 70-80% confluent. In reverse 
transfection, all three components are added to the wells at essentially the same time. 
Reverse transfection reduces the time for transfection by one day compared to forward 
transfection. As shown previously (Figure 4), forward transfection of HeLa cells with 35 
nM COBRA1 siRNA resulted in ≈ 80% knockdown on the COBRA1 protein level. For the 
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aim of selecting the method that could achieve the highest possible depletion Of COBRA1 
protein, reverse transfection method was performed and the transfection efficiency between 
both the reverse and forward transfections was compared. As shown in Figure 5, 72 hr post- 
transfection, the reverse transfection resulted in a higher efficiency (93%) than that observed 
with the forward transfection. Accordingly, the reverse transfection protocol together with 
the 35nM concentration of siRNAs was used in the subsequent transfection experiments.  
 
3.2.4 Knockdown Duration 
 
The siRNA mediated COBRA1 used in this study cause transient silencing of the expression 
of the target gene. To identify the optimum time point at which maximum knockdown of 
the effective protein levels occurs, knockdown efficiency was analysed at 24 hr, 48 hr and 
72 hr post-transfection by Western Blot and RT-PCR. As shown in Figure 5, incubating the 
cells for 72 hrs resulted in the highest silencing effect (93%) at the COBRA1 protein level, 
compared to (86%) at 48 hrs and (28%) at 24 hrs. On the other hand, the highest knockdown 
at the mRNA level (94.2%) was observed at 24 hrs post transfection compared to ≈ 80% at 
72 hrs. Since the goal is achieving an efficient knockdown at the protein level, all subsequent 
siRNA transfections in the HeLa cell line were performed at 72 hrs. 
 
3.3 COBRA1 SMARTPool siRNA Knockdown efficiency in HeLa cells 
 
To confirm the efficiency of SMARTPool siRNA in HeLa cells, transfection was repeated 
using the finally chosen optimized conditions; reverse transfection, 35Nm siRNA, 72 hrs 
and 3.75 μl Lipofectamine 3000. The expressions of COBRA1 mRNA and protein levels 
were assessed post-transfection in each of the tested groups by semi-quantitative RT-PCR 
and Western Blot respectively. Figure 6 shows that both mRNA and protein levels were 
significantly down regulated in COBRA1 siRNA HeLa treated cells compared to the 
Negative siRNA treated and the untreated cells. Data from three independent experiments 
were collected and statistical significance was computed. The COBRA1 silencing effect was 
found to be ≈ 79% at the mRNA levels (P<0.01) and 95.5% at the protein level (P<0.001). 
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It is worth mentioning that the COBRA1 knockdown did not have any significant impact on 
the overall cellular morphology of HeLa cells as observed under the inverted microscope 
(10X) when compared to the untreated or negative siRNA treated cells (Figure 7). 
 
 
 
A                                                                           B 
 
 
 
 
 
 
Figure 5. Optimization of knockdown duration via reverse transfection.  Knockdown efficiency 
was analysed at 24, 48 and 72 hours post-transfection. A) RNA expression was analysed by semi-
quantitative RT-PCR. B) Protein expression analysed by Western Blot. Bands intensities were 
quantified by ImageJ and normalized to the internal control GAPDH. Relative expression is 
expressed as fold change to siNTC. siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA. 
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A                                                                                                                            
     
 
B              
                                             
 
Figure 6. COBRA1 SMARTPool siRNA effectively silences COBRA1 expression using the 
optimized transfection conditions. A) mRNA expression was analysed by semi-quantitative RT-
PCR. B) Protein expression analysed by Western Blot. Bands intensities were quantified by ImageJ 
and normalized to the internal control GAPDH. Relative expression is expressed as fold change to 
siNTC. Data represent the means ± SD of three independent experiments (n=3). Statistically 
significant at **p<0.01, ***p<0.001(one-way ANOVA, Bonferroni’s post-test (A) and unpaired 
Student’s t-test, two tailed (B)). siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA. 
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3.4 Effect of COBRA1 silencing on the expression patterns of NELF complex 
subunits 
 
The mRNA expression levels NELF-A, NELF- C/D and NELF-E subunits were analysed 
using semi-quantitative RT-PCR in all of the tested conditions (Untreated and Negative 
siRNA compared to COBRA1 siRNA transfected cells). It was found that none of the other 
three subunits was affected by COBRA1 (NELF-B) knockdown and there was no 
statistically significant difference at the mRNA expression level among any of the tested 
conditions (P> 0.05) (Figure 8). 
 
              
             
Figure 8. COBRA1 silencing does not alter the mRNA steady-state expression of other NELF 
complex subunits.  NELF-A, NELF-C/D and NELF-E RNA expression was analysed by semi-
quantitative RT-PCR 72 hrs post-transfection in each of the tested groups. Bands intensities were 
quantified by ImageJ and normalized to the internal control GAPDH. Relative expression is 
expressed as fold change to siNTC. Data represent the means ± SD of three independent experiments 
(n=3). Results were found to be statistically non-significant at p>0.05 (one-way ANOVA, 
Bonferroni’s post-test). siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA. 
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3.5 COBRA1 Silencing effect on the proliferation of HeLa cells 
 
The effect of COBRA1 on cellular proliferation was first examined via the methyl 
tetrazolium (MTT) assay. Reverse transfection of HeLa cells with 35 nM of either the 
COBRA1 siRNA or Negative siRNA using Lipofectamine 3000 was performed in 96 well 
plates according to the manufacturers’ protocols. Percentage cell viability was used as an 
indication for the cellular proliferation. As shown in Figure 9A, there was a statistically 
significant decrease in the cellular proliferation of the COBRA1 siRNA treated cells 
compared to the untreated and mock controls but not to the negative siRNA treated cells.  
Further investigation of the effect of silencing on HeLa cells proliferation was done by 
examining the expression profile of Ki-67, an important marker for cellular proliferation. 
Ki-67 protein is  absent in the resting phase of cell cycle (G0) while it is present in all active 
phases (G1, S, G 2, and mitosis) proving that its expression is essential for cell cycle 
progression (Scholzen & Gerdes, 2000). In accordance with the previous results from the 
MTT assay, no statistically significant difference in the mRNA level of Ki-67 was observed 
compared to the negative control but there was significant decrease compared to the 
untreated cells (Figure 9B). 
 
3.6 COBRA1 Silencing effect on the migration potentials of HeLa cells 
 
The classical wound healing assay was used to investigate the effect of COBRA1 silencing 
on the migratory potential of HeLa cells (El Zeneini et al., 2017; Youssef et al., 2016). The 
cell monolayer was scratched post-transfection at the optimum knockdown time point (72 
hrs) and images at this initial timing were compared to those taken after 24 hrs (Figure 10 
A). Wound areas were analysed using ImageJ software and percentage wound closure was 
calculated based on the given areas. Results have shown that there was no statistically 
significant difference in the wound closure ability among tested conditions (p>0.05; Figure 
10 B). The COBRA1 knockdown cells showed approximately 49.7 % wound closure after 
24 hrs and the untreated, Mock-treated and siNTC treated cells showed 49.74%, 50.8% and 
56.14 % wound closure respectively.   
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Figure 9. Effect of silencing of COBRA1 on HeLa cells proliferation. A) MTT assay was used to 
analyse the viability of HeLa cells following COBRA1 knockdown compared to the control groups. 
B) RT-PCR of the proliferation marker Ki-67. Bands intensities were quantified by ImageJ and 
normalized to the internal control GAPDH. Relative expression is expressed as fold change to 
siNTC. Data represent the mean ± SD of three independent experiments (n=3). Statistically 
significant at *p<0.05, **p<0.01 (one-way ANOVA, Bonferroni's post-test). siCOBRA1: COBRA1 
siRNA, siNTC: Negative siRNA. 
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B  
 
 
Figure 10. Effect of silencing of COBRA1 on HeLa cells migration. Wound healing assay was 
used to analyse the migration rate of HeLa cells following COBRA1 knockdown. A) Images of the 
wound areas taken at  0 and 24 hrs times using phase contrast microscopy at 10X magnification. B) 
Bars are representing Percentage of wound closure in each of the tested conditions. The open areas 
were measured using ImageJ software followed by the calculation of the percentage of wound 
closure. Data represent the mean ± SD of two independent experiments (n=2). (one-way ANOVA, 
Bonferroni's post-test) (P>0.05). siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA. 
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3.7 COBRA1 Silencing effect on some cancer related genes 
  
The differential expression of a number of genes that have been previously reported to be 
commonly deregulated in cancer were examined at the mRNA level post COBRA1 siRNA 
transfection.  
3.7.1 β- Catenin 
Recent  studies has suggested the Wnt/β-catenin signalling pathways as one of the pathways 
involved in CC (Pérez-Plasencia et al., 2008). Semi-quantitative RT-PCR was carried out 
to examine the mRNA expression of the β-catenin gene following COBRA-1 silencing. As 
shown in Figure 11A, upon COBRA1 knockdown, there was a significant decrease in the 
mRNA levels of β-catenin in COBRA1 siRNA treated cells relative to the negative control.  
3.7.2 Survivin 
Survivin is one of the genes known to be commonly deregulated in cancer (Garg, Suri, 
Gupta, Talwar, & Dubey, 2016; Jaiswal, Goel, & Mittal, 2015).  RT-PCR was carried 
out to examine the mRNA expression of the survivin gene following COBRA-1 silencing. 
As shown in Figure 11B, upon COBRA1 knockdown , there was an observable decrease in 
the levels of each of the three detected isoforms of survivin (survivin-2B, survivin-DeltaEx3 
and the wild-type survivin) but it was found to be statistically significant only in survivin-
2B  and survivin-DeltaEX3 isoforms levels compared to the negative control group with a 
p-value<0.05. 
3.7.3 TFF1 
TFF1 is one of a family of highly conserved, secreted trefoil peptide proteins. It has been 
previously reported that TFF1 expression is negatively regulated by the NELF complex in 
breast cancer (Aiyar et al., 2004; Aiyar, Cho, Lee, & Li, 2007). In upper gastrointestinal 
tract cancers (UGC), overexpression of COBRA1 was associated with down regulation of 
TFF1 (McChesney et al., 2006). To determine the effect of silencing COBRA1 on the 
mRNA levels of TFF1, semi-quantitative RT-PCR was performed. As shown in Figure 12, 
there was a statistically significant increase in the TFF1 levels following COBRA1 siRNA 
transfection compared to the negative siRNA treated cells (p <0.001). 
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Figure 11. Effect silencing of COBRA1 on the expression of B-catenin and survivin.  A) Effect 
of COBRA1 knockdown on β-catenin. B) Effect of COBRA1 knockdown on survivin. mRNA 
expression was analysed by semi-quantitative RT-PCR. Bands intensities were quantified by ImageJ 
and normalized to the internal control GAPDH. Relative expression is expressed as fold change to 
the siNTC. Data represent the mean ± SD of 2 independent experiments (n = 2). Statistically 
significant at *p < 0.05 (unpaired Student t-test, two tailed). siCOBRA1: COBRA1 siRNA, siNTC: 
Negative siRNA. 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
B 
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Figure 12. Effect of silencing of COBRA1 on the expression of TFF1.  Effect of COBRA1 
knockdown on TFF1 mRNA levels was analysed by semi-quantitative RT-PCR. Bands intensities 
were quantified by ImageJ and normalized to the internal control GAPDH. Relative expression is 
expressed as fold change to the siNTC. A significant upregulation was observed in the expression of 
TFF1 following COBRA1 knockdown, relative to siNTC treated group. Data represents the mean ± 
SD of 2 independent experiments (n = 2). Statistically significant at *** p < 0.001 (one-way 
ANOVA, Bonferroni’s post-test). siCOBRA1: COBRA1 siRNA, siNTC: Negative siRNA.          
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4. DISCUSSION 
Cervical carcinoma (CC) is the fourth  leading cause of cancer-related deaths among women 
worldwide and the second most commonly diagnosed cancer in developing countries, 
accounting for an estimated 527,600 new cervical cancer cases and 265,700 deaths 
worldwide in 2012 (Torre et al., 2015). Improved understanding and increased knowledge 
of the molecular biology events associated with cervical carcinogenesis will help in 
developing more specific biomarkers and targeted therapeutics for better control of CC.   
Cofactor of BRCA1 (COBRA1) has been shown to be involved in many types of cancers 
with previous studies by our group  have identified a potential role for COBRA1 in HCC 
progression (El Zeneini et al., 2017; Youssef et al., 2016). In this study, we extended the 
scope of our group’s research to investigate the possibility of COBRA1 having a potential 
role in CC as previously detected in HCC. This was performed through analysing the 
consequences of COBRA1 Knockdown on the cellular behaviour of HeLa cells and on the 
expression pattern of some cancer-related genes.  
 
4.1 Data mining results 
 
To explore the expression pattern of COBRA1 in cervical cancer, analysis of the microarray 
data publicly available on the Oncomine cancer microarray dataset was first performed. The 
used search filter criteria resulted in the identification of four datasets from four different 
independent studies; Pyeon Multi-cancer, Scotto Cervix 2, Zhai Cervix and Biewenga 
Cervix (Biewenga et al., 2008; Pyeon et al., 2007; Scotto et al., 2008; Zhai et al., 2007). 
These studies were directed at investigating different aspects related to cervical cancer. The 
Scotto Cervix study mainly aimed at identification of the genetic expression profiles 
associated with the gain in long arm of chromosome 20 in various stages of progression of 
CC [Stages Ⅰ, Ⅱ, Ⅲ and Ⅳ]. Pyeon Multi-cancer study goal was defining similarities and 
differences of HPV-positive versus HPV-negative cancers arising in the same tissue, this 
study included samples for head and neck cancers in addition to cervical cancers [FIGO 
stage IB (80%), II/III (15%) and IV (5%)]. The Zhai cervix study aim was to test differential 
genetic expression profiles in human pre-invasive, invasive cervical squamous cell 
carcinomas and normal cervical epithelia, the stages of disease for the tumor specimens used 
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were not specified. As for Biewenga cervix study, its main objective was first to test whether 
there is a differential  gene expression profile for early stage cervical cancer tumours [FIGO 
stage ⅠB1, ⅠB2 and ⅡA] with and without lymph node metastasis, as a means for predicting 
the presence of lymph node metastasis before treatment. Subsequently, the authors 
compared gene expression profiles between healthy cervical tissue and early stage cervical 
cancer tissue. 
In two of these studies, Scotto Cervix and  Pyeon multi-cancer, COBRA1 mRNA was found 
to be significantly overexpressed in CC tissues versus normal with a fold change of  1.245 
(p= 0.003) and 1.76 (p=2.81E-4) respectively. As for Zhai cervix study, COBRA1 was found 
to be slightly upregulated with a fold change of 1.066 but this was found to be statistically 
insignificant (p=0.121). In contrast to the first three studies, in the Biewenga Cervix study 
COBRA1 was found to be downregulated with -1.1441 fold change but again this was found 
to be insignificant with a very high p-value of 0.999. 
The observed variations in microarrays data might be referred to differences in the 
experimental factors associated with each study. This could include variations in samples 
handling, RNA handling, used microarray platforms, probes sequences and differences in 
used computational methods for data analysis and validation. It is worth noting that in each 
of the Pyeon Multi-cancer, Scotto cervix and Zhai Cervix studies, studies used 
microdissection to enrich for the epithelial tumor cells before RNA extraction for microarray 
analysis, while in Biewenga  RNA was extracted from tissues of samples having >70% 
tumors thus including normal cells in addition to the cancerous ones. In addition each of the 
first three studies Affymetrix U133A oligonucleotide microarrays were used (containing the  
whole genome, 14,500 and 22,283 probe sets respectively), while in Biewenga the whole 
genome human oligonucleotide microarrays (44K Agilent) were used. The staging of the 
tumors also might contribute to the results. In each of Pyeon multi-cancer and Scotto Cervix, 
samples included in the microarray analysis represented different stages of CC [Stages Ⅰ, Ⅱ, 
Ⅲ and Ⅳ]. On the other hand, Biewenga Cervix focused on early stages of CC [stages Ⅰ and 
Ⅱ]. Tumor stages were not specified in Zhai Cervix and were referred to collectively as being 
invasive cervical cancers.  
Altogether, the in-silico analysis results suggests that there is an overexpression pattern for 
COBRA1in CC. Further meta-analysis of these datasets will help gain more necessary 
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information through correlating COBRA1 expression with the clinic-pathological features 
as the HPV-subtype, stage and size of the tumor and treatment outcome. 
 
4.2 Expression of NELF complex subunits 
 
The assembly of the four subunits of the NELF complex (NELF-A, NELF-B, NELF-C/D 
and NELF-E) is required for the formation of a functional complex. The core of the complex; 
which consists of NELF-B (COBRA1) and NELF-C/D, binds each of the NELF-A having 
the RNAPⅡ binding domain and NELF-E having the RNA binding domain (Narita et al., 
2003). This interdependent nature of the NELF subunits was reported in 2004 by Aiyar et 
al., where the binding of the COBRA1 to the activated ERα was followed by the recruitment 
of the other NELF subunits and the formation of a functional NELF complex at the 
promotors of estrogen responsive target genes (Aiyar et al., 2004).  
In this study, the knockdown of COBRA1 had no effect on the expression pattern of the 
other NELF subunits at the mRNA level. This goes in accordance with previous results from 
studies done on HCC by our group (El Zeneini et al., 2017) and other groups on UGC and 
breast cancer (McChesney et al., 2006; Sun et al., 2008). It has been previously reported 
that the depletion of one or more subunits of the NELF complex affects the other subunits 
at the protein level (Aiyar et al., 2004; Kininis, Isaacs, Core, Hah, & Kraus, 2009; Sun 
et al., 2008), which suggests the presence of post-transcriptional regulatory mechanisms that 
governs the interdependent expression of NELF subunits . It will be interesting to further 
investigate the protein levels of other subunits using Western Blot following silencing of 
COBRA1 in HeLa cells to confirm this interdependency in cervical cancer. 
 
4.3 Effect on HeLa cells proliferation and migratory abilities 
 
The ability of cancer cells to maintain a state of chronic proliferation and to metastasize 
from their initial primary tumor sites to secondary locations within the human body are 
considered to be main hallmarks of cancer (Hanahan & Weinberg, 2011). Previous studies 
related to COBRA1 and its role in cellular proliferation show some conflicting results. In 
2004, Aiyar et al. research using breast cancer cells postulated a role for COBRA1 as an 
inhibitor of estrogen mediated growth of T47D cancer cells (Aiyar et al., 2004). On the 
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other hand  COBRA1 has been found to support the proliferation of HCC with results 
showing decreased cell count and Ki-67 mRNA expression in HepG2 cells upon depletion 
of  COBRA1 compared to negative control  (El Zeneini et al., 2017).  
In the present study, the role of COBRA1 in HeLa cells proliferation has been investigated 
post-transfection first by measuring cell viability using MTT assay and second by examining 
the expression pattern of the cellular proliferation marker Ki-67 at the mRNA level across 
different tested groups. Even though there was a significant difference in percentage cell 
viability of the COBRA1 siRNA treated cells compared to the untreated (p<0.05) and mock-
treated cells (p<0.01), there was no significant difference in cell viability when compared to 
the Negative siRNA treated cells. These results were also reflected at the Ki-67 levels, where 
there was a significant difference in the expression between the untreated cells compared to 
the siRNA treated cells but again no significant difference was observed in the COBRA1 
siRNA relative to the negative siRNA treated cells. This decrease might be attributed to the 
effects on cell viability that are known to be associated with the transfection process and not 
due to the knockdown of COBRA1 itself. 
It is important to mention that under the applied experimental conditions in this study, no 
exogenous estrogen was supplied to any of the tested groups. Growing body of evidences 
suggests a role for estrogen in the development of cervical carcinogenesis. Studies done on 
HPV transgenic mice revealed that despite the fact that those mice could develop 
spontaneous tumors, mainly in the skin, they rarely develop cervical cancers spontaneously 
except when they are treated with exogenous 17 β-estradiol (S. Chung et al., 2010). In 
accordance, the findings of  a recent study in 2017  showed that estradiol could enhance the 
proliferation and inhibit the apoptosis of Hela cervical adenocarcinoma cell line (Liu, Tian, 
Yang, & Zhang, 2017). Hence, no conclusive results can be obtained from our findings 
with regard to the role of COBRA1 in HeLa cells proliferation unless the transfection was 
further performed with exogenous estrogen added to the media. 
Regarding the effect of COBRA1 silencing on the migratory abilities of HeLa cells post 
COBRA1 siRNA silencing, no significant differences in the percentage wound closure 
across 24 hrs interval were noticed among any of the tested groups. This suggests that the 
effect of COBRA1 with respect to proliferation and migration of HeLa cells might be 
governed by the same above mentioned stimulus. 
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4.4 Effect on mRNA expression level of TFF1 
  
TFF1 (also known as pS2) is one of a family of highly conserved, secreted trefoil peptide 
proteins. It is expressed mainly in the gastric epithelium as a component of the mucus layer 
protecting the stomach against mucosal injury (Soutto et al., 2015). Initially, TFF1 was 
found to be one of the estrogen inducible genes in the breast cancer cell line MCF7 
(Masiakowski et al., 1982). In 2002, a study by Leung et al. suggested that there was a 
gradual loss of TFF1 expression along the process of gastric tumorigenesis (Leung et al., 
2002). 
It has been previously reported that TFF1 expression is negatively regulated by COBRA1 
in both breast cancer and upper gastrointestinal tract cancers (Aiyar et al., 2004, 2007; 
McChesney et al., 2006) 
Notably, Aiyar et al., studies in breast cancer cell line T47D have shown that COBRA1 
causes RNAPⅡ pausing at the promoter proximal regions of TFF1 in response to the ligand- 
dependent activation of ERα (Aiyar et al., 2004). This was contradictory to the results 
obtained by Kininis et al., 2009 in MCF7 cells where the depletion of COBRA1 did not alter 
the expression of TFF1 suggesting a cell-type specific effect for COBRA1(Kininis et al., 
2009). 
In this study, examining the TFF1 mRNA levels in HeLa cell line upon COBRA1 silencing 
revealed an inverse correlation between COBRA1 and TFF1. There was a significant 
increase in TFF1 expression in COBRA1 siRNA treated cells compared to the negative 
siRNA treated cells (p<0.001). This finding suggests that COBRA1 negatively regulates 
TFF1 in HeLa cells as was previously reported in breast and UGCs. 
 
4.5 Effect on mRNA expression level of β-catenin  
 
Wnt/β-catenin signaling is involved in the control of a number of biological processes as 
cellular proliferation, fate specification, migration, cell adhesion, tissue architecture, and 
organogenesis. After Wnt couples to its receptors, one of the pathways that becomes 
activated is the canonical pathway which induces the entry of β-catenin to the nucleus where 
it acts by affecting the transcription of target genes (Pérez-Plasencia et al., 2008). Recent 
studies have suggested the Wnt/β-catenin signaling as one of the main pathways deregulated 
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in CC (Kwan et al., 2013; Pérez-Plasencia et al., 2008). Aberrant activation of Wnt/β-
catenin signaling is mainly caused by the accumulation of β-catenin,  which is closely 
associated with cervical carcinogenesis (Kwan et al., 2013). Hence, targeting this pathway 
might be a promising molecular therapeutic approach for CC.  
A recent study proposed that in gastric cancer, TFF1 depletion induces cellular proliferation 
via β-catenin signaling. TFF1 induced the activation of protein phosphatase 2A (PP2A) and 
glycogen synthase kinase 3 (GSK3β) which in turn were reported to regulate the AKT-β-
catenin signaling negatively. This was reflected in the expression levels of downstream 
targets c-MYC and Cyclin D1 (Soutto et al., 2015). In line with these results, we observed 
decreased expression of β-catenin in COBRA1 siRNA treated cells compared to negative 
siRNA treated cells. This decrease was found to be statistically significant at a p-value 
<0.05. Thus, the upregulation of TFF1 upon COBRA1 silencing was associated with 
decreased β-catenin expression.  
 
4.6 Effect on mRNA expression of survivin  
 
Survivin is a member of the inhibitor of apoptosis proteins (IAP) family with its expression 
known to be associated with cellular proliferation, angiogenesis and inhibition of apoptosis 
(Fan & Chen, 2017). Identifying the role of survivin in cancer emerged from the findings 
that it is highly expressed in most human cancers as well as during development while it is 
undetectable in non-proliferating differentiated adult tissues (Li, 2005). Survivin gene is 
located on chromosome 17q25 and it encodes multiple splice variants which include wild- 
type survivin, survivin 2B, survivin DeltaEx3, survivin 3B, survivin 2α and survivin 3α 
(Garg et al., 2016; Jaiswal et al., 2015). In cancer cells, it was reported that all these 
isoforms are expressed at very high levels compared to normal tissues and was found to be 
correlated to tumor aggressiveness and treatment resistance (Jaiswal et al., 2015). The role 
of survivin, survivin 2B and survivin DeltaEx3 in cancer has been extensively studied with 
results indicating an anti-apoptotic effect for both wild-type survivin and survivin DeltaEx3 
while survivin 2B was shown to have pro-apoptotic action. The fact that there are many 
splice variants of survivin with even different subcellular pools adds to the complexity of 
survivin’s biological functions (Garg et al., 2016; Li, 2005). It is worth mentioning that the 
expression of survivin has been reported to be regulated by the Wnt signalling pathway 
(Garg et al., 2016; Jaiswal et al., 2015). It has been proposed that the alternative splicing 
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of survivin might serve as a mechanism by which cancer cells maintain their proliferation, 
yet this requires further investigations (Garg et al., 2016). Notably, NELF complex; having 
the RNA recognition motif present in NELF-E subunit, was found to possess a dual function 
of transcription regulation and RNA processing. With COBRA1’S role in attenuating steroid 
hormones regulated transcription via recruitment of NELF complex to the promotor of target 
genes, it was also found to mediate alternative splicing by promoting inclusion of exons and 
attenuating skipping (Sun et al., 2007). 
In 2017, a systematic meta-analysis was done by Fan and Chen to evaluate the clinical 
significance of survivin expression in CC using data from 18 studies with 791 CC patients, 
1013 CIN lesions, 199 normal cervical tissues and 95 chronic cervicitis samples. Results 
indicated the presence of higher expression levels of survivin in CC relative to other tested 
groups. In addition, expression was elevated in high-grade than in low-grade patients, in 
advanced stage than in early stage patients and in patients with lymph node metastasis 
relative to those without. Also, higher expression was noted in SCC than in AC, yet this 
specific result has to be carefully considered as only 55 AC patients were included in this 
study compared to 302 SCC patients (Fan & Chen, 2017).  
In the present study, we observed decreased expression of β-catenin in COBRA1 siRNA 
treated cells compared to negative siRNA treated cells. This decrease was found to be 
statistically significant at a p-value <0.05.  The results obtained at the β-catenin mRNA 
levels were in accordance with results obtained when investigating the expression levels of 
survivin, where a decreased expression of the three isoforms; wild-type survivin, survivin 
2B and survivin DeltaEx3 was observed. Yet, this decrease was found to be statistically 
significant except for wild-type survivin. This might account for the insignificant effect of 
COBRA1 on the proliferation and migration of HeLa since the wild-type survivin, which is 
the predominantly expressed variant in HeLa, was the least to be affected by COBRA1 
depletion. Still, it will be interesting to further test the transduction of this decrease along 
the apoptosis signaling pathway by examining the protein levels of caspases 3 and 9 which 
are known to be inhibited by survivin. 
Taken together, COBRA1 depletion resulted in an increase in the expression of TFF1 
accompanied by a subsequent decrease in the β-catenin and survivin expressions at the 
mRNA level suggesting that COBRA1 might have an effect on the Wnt/β-catenin signaling 
pathway (Figure 13). It will be interesting to investigate the protein levels of the examined 
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genes using Western Blot. This could validate if the observed alterations at the mRNA levels 
were transmitted to the protein levels of the tested genes.  
Since the effect of COBRA1 on TFF1 in gastric cancer was suggested to be through the 
inhibition of the AP-1 complex transactivation of TFF1, performing Co-IP and ChIP assays 
will be of value in examining the binding of COBRA1 to AP-1 and their possible interaction 
with the TFF1 promotor. 
The observed effect of COBRA1 on the TFF1/β-catenin signaling axis may represent one of 
the molecular mechanisms underlying the potential role of COBRA1 in cervical cancer. Yet, 
the finding that the noted decrease in β-catenin and survivin was not reflected on the 
proliferation and migration abilities of HeLa is not conclusive and requires further 
investigations.   
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Figure 13. Schematic diagram illustrating the consequences of COBRA1 silencing on 
mRNA expression levels of examined genes. Successful COBRA1 depletion in HeLa cells 
caused a significant increase in the expression of TFF1 leading to decreased expression 
levels of the β-catenin and its decreased entry to the nucleus. This resulted in decreased 
levels of β-catenin downstream target gene, survivin.  
COBRA1 silencing 
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5. CONCLUSION 
As to our knowledge, this is the first study addressing the potential role of COBRA1 in CC. 
In summary, our data mining results showed that a statistically significant overexpression 
of COBRA1 in cervical carcinoma tissues versus normal cervical tissues was observed and 
found to be consistent in two microarray datasets out of the four identified by searching the 
publicly available Oncomine cancer microarray dataset. Results from the other two datasets 
were found to be contradictory and statistically insignificant. 
Results obtained from semi-quantitative RT-PCR analysis of the NELF complex subunits 
showed no significant difference in their mRNA levels upon COBRA1 knockdown which 
is consistent with previous results suggesting the presence of tight post-transcriptional 
regulation of the NELF complex. 
The insignificant effect of COBRA1 silencing on the proliferation and migration abilities of 
HeLa cells under the applied experimental conditions cannot be conclusive and requires 
further investigations.  
The observed decrease in the β-catenin expression in COBRA1 siRNA treated cells 
compared to the negative siRNA treated cells was found to be statistically significant and 
was accompanied by comparable decrease in survivin expression suggesting an effect for 
COBRA1 depletion on the Wnt/β-catenin signaling pathway. COBRA1 silencing resulted 
in a significant increase of TFF1 which could be the modulator of the effects observed on 
the β-catenin expression.  
Altogether, this study could help as an initial step in identifying the role of COBRA1 in 
cervical cancer tumorigenesis.  
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6. FUTURE DIRECTIONS 
More research is needed to further characterize the role of COBRA1 in cervical cancer and 
help clarify the possibility of it being a suitable prognostic and therapeutic target in CC. 
 Since this study was limited by the use of one type of CC cell lines; HeLa, therefore 
extending the methodology to include more CC cell lines representing the squamous cell 
cervical carcinoma which is the most common subtype will help provide a more reliable 
evaluation of COBRA1’s role in CC. 
Further analyses of COBRA1 knocked cells relative to control cells using mRNA 
microarrays will help provide a larger view of the involved genetic pathways and their 
possible role in CC progression. In addition, studying the effect of COBRA1 knockdown on 
cell cycle distribution using flow cytometry could also help clarify the role of COBRA1 
mediated regulation of gene expression in HeLa cells. It will be also interesting to investigate 
the effect of complete Knockout of COBRA1in HeLa using Crisper/Cas systems. 
It is also worth mentioning that under the applied experimental conditions, none of the tested 
conditions was supplied with exogenous estrogen during the transfection process. Hence, 
the consequences of adding exogenous estrogen together with the silencing process could 
be worth testing. 
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